Harvard Bioscience Stock Today
| HBIO Stock | USD 2.24 0.03 1.32% |
Performance0 of 100
| Odds Of DistressLess than 40
|
Harvard Bioscience is selling at 2.24 as of the 26th of November 2024; that is 1.32 percent decrease since the beginning of the trading day. The stock's open price was 2.27. Harvard Bioscience has about a 40 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Harvard Bioscience are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of December 2000 | Category Healthcare | Classification Health Care |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company was founded in 1901 and is headquartered in Holliston, Massachusetts. The company has 43.62 M outstanding shares of which 398.85 K shares are currently shorted by private and institutional investors with about 3.22 trading days to cover. More on Harvard Bioscience
Moving together with Harvard Stock
Moving against Harvard Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Harvard Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | James Green | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHarvard Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Harvard Bioscience's financial leverage. It provides some insight into what part of Harvard Bioscience's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Harvard Bioscience (HBIO) is traded on NASDAQ Exchange in USA. It is located in 84 October Hill Road, Holliston, MA, United States, 01746 and employs 391 people. Harvard Bioscience is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.01 M. Harvard Bioscience conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 43.62 M outstanding shares of which 398.85 K shares are currently shorted by private and institutional investors with about 3.22 trading days to cover.
Harvard Bioscience currently holds about 4.26 M in cash with 14.03 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Check Harvard Bioscience Probability Of Bankruptcy
Ownership AllocationHarvard Bioscience has a total of 43.62 Million outstanding shares. The majority of Harvard Bioscience outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Harvard Bioscience to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Harvard Bioscience. Please pay attention to any change in the institutional holdings of Harvard Bioscience as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Harvard Ownership Details
Harvard Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 912.6 K | |
| Meros Investment Management, Lp | 2024-09-30 | 833.6 K | |
| Renaissance Technologies Corp | 2024-09-30 | 724.1 K | |
| State Street Corp | 2024-06-30 | 709.6 K | |
| Acuitas Investments, Llc | 2024-09-30 | 491.1 K | |
| Northern Trust Corp | 2024-09-30 | 452 K | |
| Acadian Asset Management Llc | 2024-06-30 | 423 K | |
| Bard Associates Inc | 2024-09-30 | 312.4 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 274.6 K | |
| Blackrock Inc | 2024-06-30 | 2.8 M | |
| Punch & Associates Inv Mgmt Inc | 2024-09-30 | 2.8 M |
Harvard Bioscience Historical Income Statement
Harvard Stock Against Markets
Harvard Bioscience Corporate Management
| Ryan Wallace | Senior Sales | Profile | |
| Michael Rossi | Chief Officer | Profile | |
| Kara Weiner | VP Management | Profile | |
| David Sirois | Director Reporting | Profile | |
| Kenneth Olson | Ex Officer | Profile | |
| Kathryn Flynn | Corporate Controller | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.